Adolescent and Young Adult Protocol List

ANBL0032: Phase III Randomized Study of Chimeric Anti-GD2 in High Risk
Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue

Physician Summary: < age 30; High Risk: Anti-GD2 Following ASCR

COG-ANBL0532: Phase III Randomized Trial of Single vs. Tandem Myeloablative as Consolidation Therapy for High-Risk Neuroblastoma

Physician Summary: ≤ age 30: Single vs. Tandem Myeloblative as Consolidation Therapy

COG-ACNS0332: Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients

Physician Summary: > Age 21; Newly Dx: RT+ Vincristine +/- Carboplatin f/b Maint +/- Continuous Isotretinoin

AREN0532: Treatment for Very Low, Low and Standard Risk Favorable Histology Wilms Tumor

Physician Summary: < age 30; Newly Diagnosed; Stages I&II: Observation vs EE4A vs DD4A; Stage III: DD4A + XRT or Offer AREN0533

AREN0533: Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors

Physician Summary: < age 30, Newly Dx Higher Risk: VCR, AMD, DOXO per DD4A for 2 cycles + DD4A vs Regimen M

AREN0321: Treatment of High Risk Renal Tumors

Physician Summary: ≤ age 30, Newly Diagnosed Stage I-IV, Chemo –vs- Surgery Only (Ancillary AREN03B2 Required)

AALL03B1: Classification of Acute Lymphoblastic Leukemia

Physician Summary: ALL/Mandatory Biology Classification Companion to AALL0232

AALL0232: High Risk B-Precursor Acute Lymphoblastic Leukemia

Physician Summary: < 30 years of age, High Risk B-precursor (Pre-requisite = Ancillary AALL03B1)

AALL0434: Intensified Methotrexate, Nelarabine (Compound 506U78; IND#52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL)

Physician Summary: Age 0-30; Newly Diag. T-Cell ALL; Methotrexate, Nelarabine and Augmented BFM Therapy (Prerequisite AALL03B1)

AALL0433: Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies

Physician Summary:   ≤ age 30; Initial Intermed-Risk Relapse of B-precursor: Standard VCR Dosing vs Intensive VCR Dosing

ADVL04P2: A Feasibility Pilot and Phase 2 Study of Chemoimmunotherapy with Epratuzumab for Children with Relapsed CD22-Positive Acute Lymphoblastic Leukemia

Physician Summary: < age 31; Relapsed B-Precurser: Reinduction Chemo + Epratuzumab

AALL02P2: Treatment of Late Isolated Extramedullary Relapse from Acute Lymphoblstic Leukemia (ALL) (Initial CR1>/=18 months)

Physician Summary: < 30 years of Age, Late Isolated Extramedullary Relapse, (Pre-requisite = Ancillary AALL03B1)

COG-AAML07P1: A Phase II Pilot Study of Bortezomib (PS-341, Velcade, IND #58,443) Combined with Reinduction Chemotherapy in Children and Young Adults with Recurrent, Refractory or Secondary Acute Myeloid Leukemia

Physician Summary: ≤ age 21; Recurrent, Refractory or Secondary AML: Bortezomib Combined w/ Reinduction Chemotherapy

AAML0531: A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg®) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults

Physician Summary: <30 years; DeNovo Acute AML: Gemtuzumab Ozogamicin (Mylotarg®) + Conventional Chemo

COG- AHOD0831 A Non-Randomized Phase III Study of Response Adapted Therapy for the Treatment of Children with Newly Diagnosed High Risk Hodgkin Lymphoma

Physician Summary: < Age 21; Stage III/IV w/ B Symptoms; Newly Diagnosed: See Fast Facts for Tx Schema. Call Pediatric Nurses at 616.391.1230 with questions.

AEWS0331: European Ewing Tumor Working Initiative of National Groups Ewing Tumor Studies 1999 (EURO-E.W.I.N.G.99)

Physician Summary: < 50 yr of age; Isolated Pulmonary or Pleural Mets

ARST0332: Risk-Based Treatment for Pediatric Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS)

Physician Summary: < age 30, Surgery vs Surgery + XRT vs Surgery + Chemo + XRT/Surgery vs Chemo + XRT + Surgery + Chemo + XRT/Surgery (Chemo = Ifosfomide + Doxirubicin)

ARST0331: Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients with Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma

Physician Summary: Newly Dx, < 50 years old: VAC +/- XRT

ARST0531: Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma (RMS).

Physician Summary: < age 50; Newly Diagnosed: VAC vs VAC alternating w/ VI; Includes XRT

AOST0331: A Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histological Response to Pre-Operative Chemotherapy

Physician Summary: ≤ age 40; High Grade Osteosarcoma: Resectable/Histological Response to Pre-Operative Chemotherapy

AOST06P1: Feasibility and Dose Discovery Analysis of Zoledronic Acid with Concurrent Chemotherapy in the Treatment of Newly Diagnosed Metastatic Osteosarcoma

Physician Summary: ≤ age 40; No Prior Chemo; Feasibility & Dose Discovery Analysis of Zoledronic Acid with Concurrent Chemo